Immunotherapy for prostate cancer: Where we are headed

Giuseppe Schepisi, Alberto Farolfi, Vincenza Conteduca, Filippo Martignano, Delia De Lisi, Giorgia Ravaglia, Lorena Rossi, Cecilia Menna, Salvatore Roberto Bellia, Domenico Barone, Roberta Gunelli, Ugo De Giorgi

Research output: Contribution to journalReview articlepeer-review


Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.

Original languageEnglish
Article number2627
JournalInternational Journal of Molecular Sciences
Issue number12
Publication statusPublished - Dec 5 2017


  • Antibodies
  • CTLA4
  • Immunotherapy
  • PD-L1
  • PD1
  • Prostate cancer
  • Vaccines

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry


Dive into the research topics of 'Immunotherapy for prostate cancer: Where we are headed'. Together they form a unique fingerprint.

Cite this